Jose Almeida on hospital demand
From Baxter CEO Sees New Products, Expansion Driving Growth · · BloombergTelevision
“The volume of patients is not changing and we still have people getting sick, getting the flu, going to the hospital, getting treatment. This is when people use Baxter products, our products using ICU for people who are really sick, no matter the mergers in hospitals, we still have beds, people still need to be treated.”
On , Jose Almeida, Advisor at Baxter International Inc, spoke about hospital demand during Baxter CEO Sees New Products, Expansion Driving Growth on BloombergTelevision.
About Jose Almeida
In a May 2018 interview, Baxter International Chairman and CEO Jose Almeida discussed the company's growth strategy, stating that about two-thirds of projected revenue growth would come from new products and one-third from geographic expansion into markets like Japan and China. Almeida noted that while trade disputes were a concern, he said Baxter would be less affected because 90% of its products in China are made there. He described Baxter as a company focused on basic healthcare products such as injectable saline, glucose, antibiotics, and dialysis, which he said have more stable pricing than some other medical sectors. Almeida identified his biggest internal concern as shifting Baxter's culture to one of "agility, courage, and speed." He said investment decisions hinge on demographics, market size, and the company's ability to grow with the market, and that geopolitical risks are considered but do not deter investment in countries like China due to patient demand. Almeida also stated that Baxter supports broader healthcare coverage and that the volume of patients needing hospital treatment remains stable, which he said supports demand for the company's products.